News | May 03, 2025
Sanofi Consumer Healthcare India Q1 PAT up 12.9%
The Q1 2025 also witnessed a successful launch of Allegra D
The Q1 2025 also witnessed a successful launch of Allegra D
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
The company has posted net profit of Rs. 406.7 crores for the Financial Year ended March 31, 2025
The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025
Bayer expects 2025 to be the most difficult year of its turnaround
For the financial year ended March 31, 2025, Thyrocare has reported total income of Rs.702.18 crores
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat
Mistry is a seasoned finance professional having an extensive work experience spanning more than 25 years
Subscribe To Our Newsletter & Stay Updated
